A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT02763319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
Study identification
- NCT ID
- NCT02763319
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 453 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2016 (Actual)
- Primary completion
- Jun 21, 2024 (Actual)
- Completion
- Jun 21, 2024 (Actual)
- Last update posted
- Jul 17, 2025
2016 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MorphoSys Research Site | Anaheim | California | 92801 | — |
| MorphoSys Research Site | Bakersfield | California | 93309 | — |
| Morphosys Research Site | Burbank | California | 91505 | — |
| Morphosys Research Site | Fresno | California | 93701 | — |
| MorphoSys Research Site | Los Angeles | California | 90017 | — |
| MorphoSys Research Site | Whittier | California | 90603 | — |
| MorphoSys Research Site | Plainville | Connecticut | 06062 | — |
| MorphoSys Research Site | Skokie | Illinois | 60077 | — |
| MorphoSys Research Site | Detroit | Michigan | 48202 | — |
| MorphoSys Research Site | Rochester | Minnesota | 55905 | — |
| MorphoSys Research Site | Hattiesburg | Mississippi | 39401 | — |
| Morphosys Research site | Jackson | Mississippi | 39126 | — |
| Morphosys Research Site | Morristown | New Jersey | 07960 | — |
| MorphoSys Research Site | New York | New York | 10029 | — |
| MorphoSys Research Site | Stony Brook | New York | 11794 | — |
| MorphoSys Research Site | Oklahoma City | Oklahoma | 73142-2015 | — |
| MorphoSys Research Site | Knoxville | Tennessee | 37909 | — |
| Morphosys Research Site | Lubbock | Texas | 79415 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 140 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02763319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02763319 live on ClinicalTrials.gov.